References
Volpe MA, Cabelin M, Te AE, et al. A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis (CP). Presented at: American Urological Association 2001 Annual Meeting; June 2-7, 2001; Anaheim, CA.
Emili E, Lo Cigno M, Petrone U. Clinical trial of a new drug for treating hypertrophy of the prostate (Permixon®) [in Italian].
Urologia.
1983;50:1042-1048.
Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant
Serenoa repens
in benign prostatic hyperplasia.
Br J Clin Pharmacol.
1984;18:461-462.
Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomology caused by prostatic adenoma using an extract of
Serenoa repens.
Double-blind clinical study vs. placebo [in Italian; English abstract].
Minerva Urol Nefrol.
1985;37:87-91.
Boccafoschi C, Annoscia S. Comparison of
Serenoa repens
extract with placebo by controlled clinical trial in patients with prostatic adenomatosis [in Italian].
Urologia.
1983;50:1257-1268.
Smith HR, Memon A, Smart CJ, et al. The value of Permixon® in benign prostatic hypertrophy.
Br J Urol.
1986;58:36-40.
Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders.
Clin Drug Invest.
1995;9:291-297.
Mattei FM, Capone M, Acconcia A.
Serenoa repens
extract in the medical treatment of benign prostatic hypertrophy [in Italian].
Urologia.
1988;55:547-552.
Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Prostate.
1996;29:231-240.
Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent
(Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign
prostatic hyperplasia: a one-year randomized international study.
Eur Urol.
2002;41:497-507.
Menchini-Fabris GF, Giorgi P, Andreini F, et al. New perspectives on the use of
Pygeum Africanum
in prostato-bladder pathology [in Italian; English abstract].
Arch Ital Urol Nefrol Androl.
1988;60:313-322.
Carani C, Salvioli V, Scuteri A, et al. Urological and sexual evaluation of treatment of benign prostatic disease using at high doses [in Italian; English abstract].
Arch Ital Urol Nefrol Androl.
1991;63:341-345.
Bombardelli E, Morazzoni P.
Prunus africana
(Hook f.) kalkm.
Fitoterapia.
1997;68:205-218.
Bongi G. Tadenan in the treatment of prostatic adenoma. Anatomo-clinical study [in Italian].
Minerva Urol.
1972;24:129-139.
Rizzo M. Terapia medica dell'adenoma della prostata: Valutazione clinica comparativa tra estratto di Pygeum africanum ad alte dosi e placebo.
Farmacia Terapia.
1985;2:105-110.
Ranno S, Minaldi G, Viscusi G, et al. Efficacy and tolerability of prostate adenoma treatment with Tadenan 50 [in Italian; English abstract].
Prog Med.
1986;42:165-169.
Bassi P, Artibani W, De Luca V, et al. Standardized extract of
Pygeum africanum
in the treatment of benign prostatic hypertrophy. Controlled clinical study versus placebo [in Italian].
Minerva Urol Nefrol.
1987;39:45-50.
Barlet A, Albrecht J, Aubert A, et al. Efficacy of
Pygeum africanum
extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study [translated from German].
Wien Klin Wochenschr.
1990;102:667-673.
Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition.
Prostate.
1993;22:43-51.
Andro MC, Riffaud JP.
Pygeum africanum
extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience.
Curr Ther Res.
1995;56:796-817.
Kozai K, Miyake Y, Kohda H, et al. Inhibition of glucosyltransferase from
Streptococcus mutans
by oleanolic acid and ursolic acid.
Caries Res.
1987;21:104-108.
Yablonsky F, Nicolas V, Riffaud JP, et al. Antiproliferative effect of
Pygeum africanum
extract on rat prostatic fibroblasts.
J Urol.
1997;157:2381-2387.
Vontobel HP, Herzog R, Rutishauser G, et al. Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia [translated from German].
Urologe A.
1985;24:49-51.
Dathe G, Schmid H. Phytotherapy of benign prostate hyperplasia (BPH); double-blind study with stinging nettle root extract (Extractum Radicis Urticae—ERU) [translated from German].
Urologe B.
1987;27:223-226.
European Scientific Cooperative on Phytotherapy.
Urticae radix.
Exeter, UK: ESCOP; 1996-1997; Monographs on the Medicinal Uses of Plant Drugs, Fascicule 2:4.
Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
BJU Int.
1999;83:976-983.
Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Br J Urol.
1997;80:427-432.
Kadow C, Abrams PH. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia.
Eur Urol.
1986;12:187-189.
Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
Lancet.
1995;345:1529-1532.
Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
Lancet.
1995;345:1529-1532.
Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.
BJU Int.
2000;85:842-846.
Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Br J Urol.
1997;80:427-432.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton®N. Results of a placebo-controlled double-blind study [translated from German].
Urologe [B].
1988;28:301-306.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: a double-blind, placebo-controlled study.
Br J Urol.
1990;66:398-404.
Maekawa M, Kishimoto T, Yasumoto R, et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy-a multiple center double-blind study with Paraprost [in Japanese; English abstract].
Hinyokika Kiyo.
1990;36:495-516.
Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
Int Urol Nephrol.
1996;28:49-53.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton® N. Results of a placebo-controlled double-blind study [translated from German].
Urologe [B].
1988;28:301-306.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: a double-blind, placebo-controlled study.
Br J Urol.
1990;66:398-404.
Loschen G, Ebeling L. Inhibition of the arachidonate metabolism by an extract of rye pollen [in German; English abstract].
Arzneimittelforschung.
1991;41:162-167.
Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
BJU Int.
2000;86:439-442.
Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
J Urol.
2000;163:1451-1456.
Wilt T, Ishani A, MacDonald R, et al.
Pygeum africanum
for benign prostatic hyperplasia.
Cochrane Database Syst Rev.
2002;1:CD001044.
Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.
Urology.
2001;58:960-964.
Preuss HG, Marcusen C, Regan J, et al. Randomized trial of a combination of natural products (cernitin, Saw Palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH).
Int Urol Nephrol.
2001;33:217-225.
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
N Engl J Med.
2003;349:2387-2398.
Willetts KE, Clements MS, Champion S, et al.
Serenoa repens
extract for benign prostate hyperplasia: a randomized controlled trial.
BJU Int.
2003;92:267-270.
Bent S, Kane C, Shinohara K, et al. Saw Palmetto for Benign Prostatic Hyperplasia.
N Engl J Med.
2006;354:557-66.
Bent S, Kane C, Shinohara K, et al. Saw Palmetto for Benign Prostatic Hyperplasia.
N Engl J Med.
2006;354:557-66
Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
J Herb Pharmacother.
2006;5:1-11.
Lopatkin N, Sivkov A, Walther C, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms: a placebo-controlled, double-blind, multicenter trial.
World J Urol.
2005 Jun 1. [Epub ahead of print].
Melo EA, Bertero EB, Rios LA, et al. Evaluating the efficiency of a combination of pygeum africanum and stinging nettle (urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial.
Int Braz J Urol.
2005;28:418-425.
Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study.
Cancer Res.
2006;66:1234-1240.
Zegarra L, Vaisberg A, Loza C, et al. Double-blind randomized placebo-controlled study of
Bixa orellana
in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia.
Int Braz J Urol.
2007;33:493-501.
Supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Am J Epidemiol.
2008 Feb 7.
Zhang W, Wang X, Liu Y, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia.
J Med Food.
2008 Mar 21.
Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia.
Cochrane Database of Systematic Reviews.
2009; CD001423.
Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
JAMA.
2011;306(12):1344-1351.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.